Munzenberger P J, Massoud N
Department of Pharmacy Practice, College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202.
ASAIO Trans. 1991 Jan-Mar;37(1):16-8. doi: 10.1097/00002480-199101000-00006.
This analysis of gentamicin pharmacokinetics involved 15 neonates supported by extracorporeal membrane oxygenation (ECMO). Two sets of blood samples were obtained from each neonate while supported by ECMO. The mean volume of distribution, elimination half-life, and clearance calculated from the first set of samples were 0.62 liters/kg, 7.6 hours, and 1.17 ml/kg/minute, respectively. Mean values from the second set of samples were 0.61 liters/kg, 7.9 hours and 0.99 ml/kg/minute, respectively. There were no statistical differences (p greater than 0.05) between the pharmacokinetics calculated from the first and second set of samples. A comparison of our results with those of others involving neonates not supported by ECMO failed to demonstrate any major impact of ECMO on the pharmacokinetics of gentamicin.
这项对庆大霉素药代动力学的分析涉及15名接受体外膜肺氧合(ECMO)支持的新生儿。在ECMO支持期间,从每名新生儿采集了两组血样。根据第一组样本计算出的平均分布容积、消除半衰期和清除率分别为0.62升/千克、7.6小时和1.17毫升/千克/分钟。第二组样本的平均值分别为0.61升/千克、7.9小时和0.99毫升/千克/分钟。从第一组和第二组样本计算出的药代动力学之间无统计学差异(p大于0.05)。将我们的结果与其他涉及未接受ECMO支持的新生儿的结果进行比较,未能证明ECMO对庆大霉素药代动力学有任何重大影响。